JAZZ (Jazz Pharmaceuticals): The EPS ’Miss’ Was a $77M Check It Won’t Add Back — Q2 2026

Jazz Pharmaceuticals plc (JAZZ) Q2 2026 — Reported after the close on August 3 (three months ended June 30, 2026). Total revenue $1,208.3M, +15.6%, a company record and ~$94M above consensus. GAAP gross margin 90.4%. GAAP diluted EPS $2.78 (from -$11.74). Non-GAAP adjusted EPS $5.71 vs $6.18 expected — but the entire shortfall is $77.0M of acquired IPR&D ($0.94/share after tax) that Jazz, unlike most of pharma, does NOT add back; ex-IPR&D adjusted EPS was $6.65, a 47-cent BEAT. 2026 revenue guidance RAISED to $4.60-4.75B from $4.25-4.50B. The stock closed at $251.58, up 118% in twelve months, and traded $256 after hours. The headline said Jazz missed. It did not. The $0.47 shortfall is one line: $77.0M of acquired in-process R&D — upfront payments to AbCellera and Werewolf Therapeutics — which Jazz leaves inside BOTH GAAP and adjusted earnings while most peers strip it out. Add it back and adjusted EPS was $6.65 against $6.18 expected. Meanwhile the patent cliff everyone prices this stock for has already happened (Xyrem is down to $30.5M a quarter) and the next one is contracted away: all ten Epidiolex generic filers are settled and licensed to launch in the very late 2030s. THE CALL: BUY (4/5, A COMPANY GROWING 16% AND PRICED FOR ZERO GROWTH, FOREVER) — base-case value ~$280.0 vs ~$251.58 today. KEY METRICS: - THE CALL: BUY 4/5 - fair value ~$280 vs the $251.58 close (+11%); Street consensus Buy (43 buy / 5 hold / 0 sell, 48 ratings on file) with an average target of $266.55 (range $229-$307, median $260), only +6%. We AGREE on the rating and are modestly more BULLISH on the number. Note the oddity: a near-unanimous Buy with a target 6% above spot is a Hold wearing a Buy's clothing. - DCF GRID (bear/base/bull x 8/9/10%): $214-187-165, $304-261-228, $396-334-287. Probability-weighted 25/50/25 gives $261 at 9% and $305 at 8%; we sit at $280 on an 8.5% rate (0.36 beta, a decade of contracted exclusivity). Base case: 2026 owner earnings ~$1.30B (adjusted net income less stock comp after tax less net capex; cross-checks to 1H26 operating cash flow of $823.9M) growing 8/7/6/5/4%, 1.0% terminal. REVERSE DCF: at $251.58 the enterprise is priced at $18.53B, which at 8% with 1% terminal growth demands ~$1.30B of owner earnings FLAT FOREVER - exactly what Jazz earns today. The market is paying for zero growth in perpetuity. - THE PRINT: total revenue $1,208.3M (+15.6%, a record) vs ~$1,114M consensus; net product sales $1,156.1M (+17.3%); GAAP gross margin 90.4% (vs 88.9%); GAAP operating income $248.2M (vs -$686.4M); GAAP diluted EPS $2.78 (vs -$11.74); non-GAAP adjusted EPS $5.71 (vs -$8.25); acquired IPR&D $77.0M in BOTH measures. Diluted shares 61.2M to 69.4M (+13%) as the exchangeables came into the money at $153.05. - BY MEDICINE (Q2 2026 / Q2 2025): Xywav $471.2M / $415.3M (+13.5%, ~525 net patient adds, ~17,125 active patients: 11,275 narcolepsy + 5,850 IH). Epidiolex/Epidyolex $292.1M / $251.7M (+16.0%). Zepzelca $105.8M / $74.5M (+42.0%). Rylaze/Enrylaze $99.5M / $100.7M (-1.2%). Defitelio $62.0M / $48.1M (+28.9%). Modeyso $48.2M / $0.5M. Vyxeos $31.4M / $44.9M (-30.1%). Xyrem $30.5M / $35.4M (-13.8%). Ziihera $15.4M / $6.0M. Franchises: Sleep $501.7M (41.5% of revenue, down from 43.1%), Epilepsy $292.1M, Oncology $362.3M (+31.9%). - THE ADJUSTMENT BRIDGE, INTERROGATED: GAAP $2.78 to non-GAAP $5.71 is a $2.93/share gap. Intangible amortisation $170.0M ($2.45/sh) is 84% of the gross add-back - and it is the amortisation of assets Jazz BOUGHT (Epidiolex from GW, Ziihera from Zymeworks, Modeyso from Chimerix), i.e. the deferred purchase price of the revenue being reported. Plus share comp $73.3M ($1.06), inventory step-up $16.6M ($0.24), less tax effect -$56.3M. Acquired IPR&D is NOT added back. - THE CLIFF IS BEHIND THEM: all ten Epidiolex ANDA filers (Teva, Padagis, Apotex, InvaGen, Lupin, Taro, Zenara, MSN, Alkem, Ascent) are SETTLED and licensed to launch in the very late 2030s. Xyrem, once a ~$2B franchise, is down to $30.5M a quarter and the high-sodium authorised-generic royalty fell 22% to $42.2M - that cliff already happened and revenue still grew 16%. BALANCE SHEET: repaid $1.0B of 2.00% exchangeables IN CASH at maturity on June 15 (plus 1,890,193 shares for the conversion premium); debt principal $5.4B to $4.4B ($1.9B term loans, $1.5B 4.375% secured notes due 2029, $1.0B 3.125% exchangeables due 2030); cash and investments $2.20B; $885M undrawn revolver; net debt ~$2.2B (~1.0x). NO shares repurchased in 1H26 ($225M still authorised) vs $125.0M in 1H25. - WHAT WE DO NOT LIKE: zero buyback against a 13% rise in diluted shares; $170M a quarter of amortising purchased revenue; Zepzelca grew 42% but Jazz will file in 3Q26, in alignment with FDA, to REMOVE the second-line indication entirely after the LAGOON trial (first-line maintenance unaffected); Vyxeos -30% and Rylaze -1.2%; Xywav concentration at ~41% of net product sales against a live competitor in Avadel; MFN/IRA drug-pricing pressure. What to watch: Bullish: FDA approval of zanidatamab in 1L HER2+ gastroesophageal adenocarcinoma on or before the August 25 PDUFA date (a far larger population than Ziihera's current biliary-tract indication, and essentially none of it is in guidance); the second interim HERIZON-GEA-01 overall-survival readout in 3Q26; Xywav net patient adds holding above 500 a quarter; the buyback restarting. Get the first and third and we move toward $330. Bearish: Xywav net adds below ~400 (Avadel taking share); a 2027 revenue guide that does not start with a five; a complete response letter on August 25; another large acquired-IPR&D quarter without a matching asset. Any two and we are nearer $190. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.